Silence Therapeutics (SLN) Fundamentals 2026 — Revenue Analysis | SniperIQ

1.48 on the NASDAQ. This SniperIQ fundamentals page covers Silence Therapeutics's valuation, profitability (net margin -9243.0%), revenue ($559,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Silence Therapeutics's market cap?

Silence Therapeutics (SLN) has a market capitalization of approximately $542M, trading at

1.48 on the NASDAQ. Market cap moves with the live share price.

What is Silence Therapeutics's P/E ratio?

Silence Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 11.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Silence Therapeutics?

Silence Therapeutics runs a net profit margin of -9243.0%, a gross margin of 66.4%, and an operating margin of -9396.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Silence Therapeutics generate?

Silence Therapeutics reported revenue of $559,000 for fiscal year 2025, with net income of -$89M and earnings per share (EPS) of -1.89. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Silence Therapeutics pay a dividend?

Silence Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Silence Therapeutics financially healthy?

Silence Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 9.83x, with a market beta of 1.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Silence Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Silence Therapeutics (SLN) the key facts are: market cap $542M, revenue $559,000, 52-week range 4.19-11.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.